Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 35Lymphoma, Follicular 14Lymphoma, Non-Hodgkin 9Waldenstrom Macroglobulinemia 8Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Mantle-Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Leukemia, Myeloid, Acute 4Leukemia 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Thrombocytosis 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoid Malignancies 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

idelalisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoid Malignancies × idelalisib × Clear all
NCT02739360 2020-03-04

Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

Gilead Sciences

Phase 4 Terminated
3 enrolled 5 charts

Lymphoid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡